J.P. Morgan keeps AUD 3.10 target for Sigma Healthcare stock

Sigma Healthcare (AU000000SIG5) drew a fresh analyst endorsement when Markets Insider reported on October 23, 2026 that J.P. Morgan had maintained its Buy rating and AUD 3.10 price target in a report dated October 22. Sigma Healthcare stock was trading after hours at EUR 1.73 at Lang & Schwarz on October 27, 2026 at 7:19 p.m. CET.

Target support meets operating scale

The analyst view follows Sigma's first full fiscal year as a merged group. At the October 21 annual meeting, the company presented fiscal 2026 revenue of AUD 10.8 billion, up 15.5 percent, and normalized EBIT of AUD 1.09 billion, up 20.6 percent, according to Sigma Healthcare. Normalized NPAT increased 22.3 percent to AUD 732.3 million for the same fiscal year.

Sales update adds a second signal

The annual meeting also gave investors a current operating marker. Australian Chemist Warehouse branded stores delivered 12.1 percent sales growth and 9.8 percent like-for-like growth through October 16, 2026, while international stores posted 30.2 percent sales growth and 15.8 percent like-for-like growth in the first quarter of fiscal 2027, the company presentation said.

Price position and valuation

Sigma's ASX quote closed at AUD 2.73 on October 27, 2026, with a 52-week range of AUD 2.47 to AUD 3.20 and volume of 14,712,449 shares. The market capitalization was AUD 31.4 billion. The shares stood 10.53 percent above the 52-week low and 14.69 percent below the high, calculated from the same Australian-market figures.

The analyst comparison remains specific. MarketScreener listed a Jefferies target of AUD 3.15 from October 21 and an average target of AUD 3.148 from 16 analysts. Sigma's current Australian price of AUD 2.73 is 15.31 percent below that average target.

What comes next for Sigma?

The next earnings report is scheduled for March 4, 2027, according to TradingView. Until then, the central investor test is whether the fiscal 2027 sales trajectory can support the merger-driven improvement already visible in fiscal 2026 margins and earnings.

Market view stays tied to execution

For investors, Sigma combines a large operating base with a wide valuation spread across the analyst community. The fiscal 2026 revenue increase of 15.5 percent was slower than normalized NPAT growth of 22.3 percent, while the current Australian quote remains below the reported analyst targets. That combination leaves execution, integration benefits and international sales as the measurable markers for the next report.

The further course of trading is shown by the continuously updated real-time quote of Sigma Healthcare stock.

Market context: Market report S&P/ASX 200.

More news and analyses on Sigma Healthcare stock